Human Vaccines & Immunotherapeutics

Real-World Evidence in COVID-19 Prevention

We are pleased to announce a new Article Collection in Human Vaccines & Immunotherapeutics, dedicated to the important role of real-world evidence (RWE) studies in the prevention of COVID-19.

The world was taken by storm by the global COVID-19 pandemic. The scientific and medical community quickly rallied together to develop and test numerous COVID-19 vaccines of different designs, which have become a mainstay annual vaccine in developed countries. While randomized controlled trials remain the gold standard for understanding the efficacy and safety of vaccines under highly controlled conditions, RWE studies help to reveal a vaccine’s true effectiveness and safety in everyday patient populations. Integration of RWE into decision-making processes reflects its growing importance as a supportive tool for both clinicians and patients, but also in shaping broader healthcare decisions and regulatory approvals.

Given the global importance of RWE in understanding and managing COVID-19 in a variety of patient populations, Human Vaccines & Immunotherapeutics invites submissions of original research articles, reviews, and perspectives exploring real-world evidence in COVID-19 immunization.

The Collection, led by Editor-In-Chief Dr. Ronald Ellis, will be included in Taylor & Francis’ Real-World Evidence Series. Papers published within the series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

The Collection is open to submissions across the broad spectrum of RWE research, with a particular interest in the following areas:

• Clinical Trials evaluating the effectiveness and safety of vaccination and related interventions in routine, real-world clinical practice.
• Observational cohort studies using real-world data.
• Patient registry studies utilizing data from IQVIA, SEER, NHANES & UK Biobank. All patient registry studies must receive approval from relevant ethics committee and/or institutional review board before any patient data collection or enrolment begins.
• Comparative Effectiveness, Pharmacovigilance and Drug Safety research utilizing Electronic Health Record (HER) data.
• Integration of RWE with health technology & AI, where results provide actionable clinical insights.

Keywords: Real-world evidence; COVID-19 vaccine; COVID-19; SARS-CoV2

Meet the Guest Advisor

Dr. Ronald Ellis has >40 years of scientific, managerial and executive R&D experience in start-up, small, medium and large biotech, and pharma companies, and is an independent consultant. He has championed or led R&D efforts on a wide range of vaccines and immunotherapeutics from discovery or in-licensure through development and clinical to commercial licensure and launch in major markets. These efforts have included several licensed products which together have annual worldwide sales ~$12B.